Search Results - Krisha McKee

  • Showing 1 - 2 results of 2
Refine Results
  1. 1

    Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain by Young D. Kwon, Amarendra Pegu, Eun Sung Yang, Baoshan Zhang, Michael F. Bender, Mangaiarkarasi Asokan, Qingbo Liu, Krisha McKee, Bob C. Lin, Tracy Liu, Mark K. Louder, Reda Rawi, Mateo Reveiz, Andrew J. Schaub, Chen-Hsiang Shen, Nicole A. Doria-Rose, Paolo Lusso, John R. Mascola, Peter D. Kwong

    Published 2023-12-01

    The amino-acid composition of the immunoglobulin variable region has been observed to impact antibody pharmacokinetics (PK). Here, we sought to improve the PK of the broad HIV−1-neutralizing VRC01-class antibodies, VRC07-523LS and N6LS, by reducing the net positive charge in their variable domains....

    Full description

    Get full text
    Article
  2. 2

    Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency by Baoshan Zhang, Jason Gorman, Young D. Kwon, Amarendra Pegu, Cara W. Chao, Tracy Liu, Mangaiarkarasi Asokan, Michael F. Bender, Tatsiana Bylund, Leland Damron, Deepika Gollapudi, Paula Lei, Yile Li, Cuiping Liu, Mark K. Louder, Krisha McKee, Adam S. Olia, Reda Rawi, Arne Schön, Shuishu Wang, Eun Sung Yang, Yongping Yang, Kevin Carlton, Nicole A. Doria-Rose, Lawrence Shapiro, Michael S. Seaman, John R. Mascola, Peter D. Kwong

    Published 2023-12-01

    Antibody CAP256-VRC26.25 targets the second hypervariable region (V2) at the apex of the HIV envelope (Env) trimer with extraordinary neutralization potency, although less than optimal breadth. To improve breadth, we linked the light chain of CAP256V2LS, an optimized version of CAP256-VRC26.25 curre...

    Full description

    Get full text
    Article